- Home
- LYEL vs ESGRO Comparison
LYEL vs ESGRO Comparison
Compare LYEL & ESGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- ESGRO
- Stock Information
- Founded
- LYEL 2018
- ESGRO N/A
- Country
- LYEL United States
- ESGRO Bermuda
- Employees
- LYEL N/A
- ESGRO 790
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- ESGRO Property-Casualty Insurers
- Sector
- LYEL Health Care
- ESGRO Finance
- Exchange
- LYEL Nasdaq
- ESGRO Nasdaq
- Market Cap
- LYEL 207.7M
- ESGRO N/A
- IPO Year
- LYEL 2021
- ESGRO N/A
- Fundamental
- Price
- LYEL $9.84
- ESGRO $19.30
- Analyst Decision
- LYEL Sell
- ESGRO
- Analyst Count
- LYEL 2
- ESGRO 0
- Target Price
- LYEL $15.00
- ESGRO N/A
- AVG Volume (30 Days)
- LYEL 148.8K
- ESGRO N/A
- Earning Date
- LYEL 08-06-2025
- ESGRO N/A
- Dividend Yield
- LYEL N/A
- ESGRO N/A
- EPS Growth
- LYEL N/A
- ESGRO N/A
- EPS
- LYEL N/A
- ESGRO N/A
- Revenue
- LYEL $65,000.00
- ESGRO N/A
- Revenue This Year
- LYEL N/A
- ESGRO N/A
- Revenue Next Year
- LYEL N/A
- ESGRO N/A
- P/E Ratio
- LYEL N/A
- ESGRO N/A
- Revenue Growth
- LYEL N/A
- ESGRO N/A
- 52 Week Low
- LYEL $7.65
- ESGRO N/A
- 52 Week High
- LYEL $38.40
- ESGRO N/A
- Technical
- Relative Strength Index (RSI)
- LYEL 52.64
- ESGRO 40.63
- Support Level
- LYEL $9.11
- ESGRO $19.11
- Resistance Level
- LYEL $10.41
- ESGRO $20.58
- Average True Range (ATR)
- LYEL 0.61
- ESGRO 0.35
- MACD
- LYEL 0.04
- ESGRO -0.08
- Stochastic Oscillator
- LYEL 70.77
- ESGRO 52.12
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ESGRO Enstar Group Limited Depository
Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through two reportable segments: Run-off segment and Investments segment.